This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Better Platinum in Head and Neck Cancer?

Peter Volling, MD; Michael Schröder, MD; Winrich Rauschning, MD; Wolf Achterrath; Eberhard Stennert, MD

Arch Otolaryngol Head Neck Surg. 1989;115(6):695-698.

Abstract
• Chemotherapeutic regimens containing cisplatin are the most effective ones in the treatment of squamous cell carcinoma of the head and neck. Because of the high rate of dose-limiting side effects of cisplatin, carboplatin, a second-generation cisplatin analogue, was tested in a phase II trial with fluorouracil in 55 previously untreated patients with advanced carcinoma of the head and neck. Among the 52 patients who completed the study, there were 17 complete responses (33%), 28 partial responses (54%), five patients with no change (10%), and two with progressive disease (4%). Toxic side effects of all courses summed together included leukopenia in 65% of courses, thrombocytopenia in 45% of courses, nausea or vomiting in 29% of courses, and change in serum creatinine level in 3% of courses. These data were compared with the results of our study with cisplatin and fluorouracil in comparable patients and indicated that carboplatin and fluorouracil is better for induction chemotherapy in the treatment of head and neck cancer than cisplatin and fluorouracil due to similar effectiveness but less toxic effect.

(Arch Otolaryngol Head Neck Surg 1989;115:695-698)

Author Affiliations
From the HNO-Universitätskliniks, Cologne (Drs Volling and Stennert) and Göttingen (Dr Schröder), West Germany; Medizinische Universitätsklinik, Göttingen (Dr Rauschning); and Department of Clinical Research Anticancer, Bristol-Myers GmbH, Neu-Isenburg, West Germany (Mr Achterrath).

Footnotes
Accepted for publication Nov 4, 1988.

Read before the Second International Conference on Head and Neck Cancer, Boston, Aug 4, 1988.

Reprint requests to HNO-Universitätsklinik, Joseph-Stelzmann-Str 9, 5000 Köln 41, West Germany (Dr Volling).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Carboplatin-Radiation Interaction in Squamous Cell Carcinoma Cell Lines
Pekkola-Heino et al.
Arch Otolaryngol Head Neck Surg 1992;118:1312-1315.
ABSTRACT